Triumph Financial's (NASDAQ: TFIN) stock rating was reaffirmed by B.Riley, maintaining a Neutral stance with a price target of $65.00.
The financial firm's analyst provided insights into CytoSorbents Corporation's (NASDAQ: CTSO) recent regulatory submission.
CytoSorbents announced on Monday that it had submitted a De Novo medical device application for its DrugSorb-ATR to the U.S. FDA.
The product, designed for patients on ticagrelor undergoing coronary artery bypass graft surgery, has been granted Breakthrough Device Designation, which may expedite the review process, potentially leading to a regulatory decision within 6 to 12 months.
The analyst noted that CytoSorbents is also preparing to submit an application to Health Canada, awaiting the Medical Device Single Audit Program certification, which is expected to be granted in the following weeks.
Decisions from both the FDA and Health Canada are anticipated in 2025. This follows the results from the STAR-T trial, where DrugSorb-ATR met its primary safety endpoint but did not meet the primary effectiveness endpoint in the overall patient population.
CytoSorbents has decided to proceed with submissions focusing on the isolated coronary artery bypass graft (iCABG) patient subgroup, where the device showed a distinct benefit.
Although the FDA has a history of approving medical devices with mixed trial results, the analyst conveyed a cautious stance on the approval prospects of DrugSorb and has not factored it into the current valuation. However, the potential for upside in the event of approval was acknowledged.
Additionally, CytoSorbents provided a preliminary report on its third-quarter product revenue for 2024. The company expects sales to range between $8.3 million and $8.5 million, indicating a 7-10% year-over-year growth from $7.8 million in the third quarter of 2023.
The figures are consistent with B.Riley's projection of $8.5 million but fall slightly short of the consensus estimate of $8.7 million. A temporary manufacturing issue led to a reduced number of CytoSorb devices produced and a contracted product gross margin of 50-60% in the third quarter of 2024, compared to 71% in the same quarter of the previous year.
In other recent news, Triumph Financial reported growth in its second quarter financial results, with an emphasis on the expansion of TriumphPay. The company projects EBITDA margins between 50% and 70%, contributing to a potential $1 billion revenue opportunity.
Triumph Financial's earnings and revenue growth have also been noted in its Payments segment, attributed to new broker clients and increased adoption rates. The company has $190 million in excess capital, preparing for potential recession conditions and merger and acquisition opportunities.
In recent executive role changes, Ms. Gail Lehmann has transitioned from her role as Executive Vice President and Chief Regulatory and Governance Officer, focusing now on special projects and facilities management. Additionally, Jamie Paterson was appointed as the new Executive Vice President and Chief Operating Officer of Banking Operations for its subsidiary TBK Bank, SSB.
During an earnings call, Triumph Financial outlined its strategic initiatives and financial targets, focusing on achieving significant trucking industry network density and monetizing its services. The company aims to reach 50% to 80% network density by 2024 or 2025.
InvestingPro Insights
Triumph Financial's current market dynamics offer interesting insights for investors. According to InvestingPro data, the company's market capitalization stands at $1.78 billion, with a P/E ratio of 67.88, suggesting a premium valuation. This aligns with an InvestingPro Tip indicating that Triumph Financial is "trading at a high earnings multiple."
Despite the high valuation, Triumph Financial has demonstrated strong performance over the long term. InvestingPro Tips highlight that the company has shown "high return over the last decade" and "strong return over the last five years." This historical performance may justify the current premium valuation to some extent.
However, investors should note that the company faces some near-term challenges. An InvestingPro Tip reveals that "5 analysts have revised their earnings downwards for the upcoming period," which could impact the stock's performance in the short term. Additionally, the company "suffers from weak gross profit margins," which may affect its profitability.
For those considering an investment in Triumph Financial, it's worth noting that InvestingPro offers 8 additional tips that could provide further insights into the company's financial health and prospects. These additional tips, available with an InvestingPro subscription, could be valuable for making a more informed investment decision in light of the recent analyst reaffirmation and the company's current market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.